Peptide History advanced
History of Peptide Drug Conjugates
The evolution of peptide-drug conjugates from early concepts to approved therapies.
By Encyclopeptide Editorial | 1 min read
conjugates adc oncology history
Overview
Peptide-drug conjugates (PDCs) combine the targeting specificity of peptides with the cytotoxic power of chemotherapeutic agents.
Key Developments
- 1990s: Concept of targeted drug delivery
- 2000s: First PDC clinical candidates
- 2010s: Bicycle toxin conjugates enter trials
- 2020s: Multiple PDCs in late-stage development
Advantages Over ADCs
- Smaller size enables better tumor penetration
- Faster clearance reduces systemic toxicity
- Simpler manufacturing
- Lower immunogenicity potential
Current Pipeline
BT1718, BT5528, and other Bicycle toxin conjugates are in clinical development for solid tumors.
References
- Source: ENCP Peptide Database
- Category: Peptide History
Test Your Knowledge
Reinforce what you learned about History of Peptide Drug Conjugates with interactive quizzes on Wikipept.
Take a Quiz on Wikipept